tebentafusp

Contraindicated in:

OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Rep: Women of reproductive potential;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: edema, hypotension, hypertension, tachycardia

Derm: cutaneous edema, dry skin, erythema, hair color changes, hypopigmentation, pruritus, rash, alopecia, flushing, hyperpigmentation

Endo: hyperglycemia, hypoglycemia

F and E: hypercalcemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia

GI: ↑amylase, ↑lipase, ↑liver enzymes, abdominal pain, diarrhea, hyperbilirubinemia, hypoalbuminemia, nausea, vomiting, constipation, oropharyngeal pain

GU: ↑serum creatinine

Hemat: anemia, lymphocytopenia, neutropenia, thrombocytopenia

Metab: ↓appetite

MS: arthralgia, muscle spasm, myalgia, pain

Neuro: fatigue, headache, dizziness, paresthesia

Resp: dyspnea

Misc: chills, cytokine release syndrome (CRS), fever, night sweats

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Solution for injection: 100 mcg/0.5 mL

Route/Dosage ⬆ ⬇

IV (Adults ): Day 1: 20 mcg as single dose; Day 8: 30 mcg as single dose; Day 15: 68 mcg as single dose; Day 22 and beyond: 68 mcg once weekly until disease progression or unacceptable toxicity.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Binds to a gp100 peptide presented by HLA-A*02:01 on the surface of uveal melanoma tumor cells. Once bound, this complex acts as a T-cell engager, binding to the CD3 receptor on T-cells. T cells are then activated, which causes release of proinflammatory cytokines, resulting in direct lysis of uveal melanoma tumor cells.

Therapeutic effects:

Improved overall survival and progression-free survival.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: T-cell engagers

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Minimal distribution to tissues.

Metabolism/Excretion: Broken down into small peptides and amino acids. Excretion pathway unknown.

Half-Life: 7.5 hr.

Time/Action Profile ⬆ ⬇

(increase in proinflammatory cytokine concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	8–24 hr	unknown‡

‡Concentrations returned to baseline before next dose.

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
Advise patient to notify health care professional for symptoms of CRS (fever, fatigue, dizziness, nausea, headache, muscle and joint pain).
Advise patient to notify health care professional for progressive or intolerable skin reactions.
Advise patient to notify health care professional for signs and symptoms of liver toxicity (right-sided abdominal pain, jaundice).
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Rep: May cause fetal harm. Advise women of reproductive potential to use effective contraception and to not breastfeed during and for 1 wk after last dose. Advise patient to notify health care professional if pregnancy is planned or suspected.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

80446- Immunocore Commercial LLC
- 80446-401- KIMMTRAK
  - 80446-401-01- 1 VIAL, GLASS in 1 CARTON (80446-401-01) / .5 mL in 1 VIAL, GLASS

82507- AGC Biologics A/S
- 82507-003-
  - 82507-003-01- 2000 mL in 1 BOTTLE (82507-003-01)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇